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Abstract
Background/Aim. Women with diabetes, especially diabetes
type 1, have worse pregnancy outcomes, as well as increased
incidence of spontaneous abortions, pre-eclampsia, fetal mac-
rosomia, preterm delivery, congenital anomalies and perinatal
mortality. The aim of this study was to analyze the course and
outcome of pregnancy in the patients with diabetes in relation
to the group of healthy women regarding preterm delivery,
perinatal morbidity and mortality. Also, the aim was to com-
pare pregnancy outcomes in the patients with pre-existing dia-
betes type 1 and the patients with gestational and diabetes type
2. Methods. This retrospective study included 156 diabetic
women treated at the Clinic of Endocrinology, Diabetes and
Metabolic Diseases and Gynecology and Obstetrics Clinic of
the Clinical Center of Vojvodina from 2006 to 2010. There
were 94 patients with gestational diabetes, 48 with type 1 dia-
betes, and 14 patients with type 2 diabetes. The control group
included 106 healthy women hospitalized at the Gynecology
and Obstetrics Clinic. Results. The women with type 1 dia-
betes presented with a statistically significantly higher inci-
dence of cesarean section than those without diabetes, or with
type 2 or gestational diabetes (p < 0.0001); the women with
type 1 diabetes delivered at an earlier week of gestation (WG)
in regard to women without diabetes, or with type 2 or gesta-
tional diabetes (p = 0.0017 and p = 0.02, respectively). The in-
cidence of perinatal morbidity: hypoglycemia (p < 0.001),
pathological jaundice (p = 0.0021), and other neonatal pa-
thologies at birth (p = 0.0031), was statistically significantly
higher and Apgar scores after 1 minute (p = 0.0142) and after
5 minutes (p = 0.0003) were statistically significantly lower in
the patients with diabetes compared to the healthy women.
The women with type 2 and gestational diabetes were statisti-
cally significantly older than those with type 1 diabetes (p =
0.001). A higher incidence of fetal macrosomia in the women
with gestational and type 2 diabetes compared to those with
type 1 diabetes was at the borderline of statistical significance
(p = 0.07), whereas the incidence of hypoglycemia of newborn
was statistically significantly higher in the patients with type 1
diabetes (p < 0.0001). Glycosylated hemoglobin (HbA1c) lev-
els were statistically significantly higher in the diabetic women
giving birth during and before the week of gestation 36 (p =
0.0087), but there were no differences in HbA1c levels in re-
gard to fetal macrosomia (p = 0.45) and congenital abnormali-
ties (p = 0.32). Conclusion. The results of our study show a
higher incidence of perinatal fetal morbidity (hypoglycemia,
jaundice, respiratory distress syndrome) in the patients with
type 1, type 2 and gestation diabetes than in the healthy con-
trols. Also, we found a higher incidence of cesarean section in
the patients with type 1 diabetes than in those with type 2,
gestation diabetes and healthy controls. Although delivery in
the patients with type 1, type 2 and gestational diabetes was
completed approximately one to two weeks earlier compared
to the healthy controls there was no statistically significant dif-
ference in the incidence of preterm delivery ( 36th week of
gestation) between the women with diabetes and healthy con-
trols. Preterm delivery associated with poorer glycaemic con-
trol reflected through higher values of HbA1c in third trimes-
ter. Risks from adverse pregnancy outcomes may be reduced
to minimum by adequate preconception counseling of diabetic
patients and early diagnosis of diabetes in pregnancy, in order
to achieve glycemic control during organogenesis and within
pregnancy and through the teamwork of endocrinologists, gy-
necologists and pediatricians.
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Apstrakt
Uvod/Cilj. Žene sa dijabetesom, a posebno one sa tipom
1, imaju lošiji ishod trudnoýe u odnosu na žene bez dijabe-
tesa, pre svega zbog veýe uÿestalosti spontanih pobaÿaja,
preekalmpsije, makrozomije ploda, prevremenog poroĀaja,
kongenitalnih malformacija i perinatalnog mortaliteta ploda.
Cilj ispitivanja bio je analiza toka i ishoda trudnoýe kod
bolesnica sa dijabetesom u odnosu na kontrolnu grupu
zdravih žena, a u odnosu na prevremeni poroĀaj, perinatalniStrana 908 VOJNOSANITETSKI PREGLED Volumen 71, Broj 10
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morbiditet i mortalitet, kao i ishod trudnoýe kod bolesnica
sa preegzistentnim dijabetesom tipa 1 u odnosu na bolesnice
sa gestacijskim i dijabetesom tipa 2. Metode. Retrospek-
tivno istraživanje sprovedeno je na 156 žena sa dijabetesom
leÿenih na Klinici za endokrinologiju, dijabetes i bolesti
metabolizma i Klinici za ginekologiju i akušerstvo Kliniÿkog
centra Vojvodine tokom perioda 2006–2010. godine.
Gestacijski dijabetes imalo je 94 ispitanice, dijabetes tip 1 48,
a dijabetes tip 2 14 ispitanica. Kontrolnu grupu ÿinilo je 106
zdravih žena hospitalizovanih u Klinici za ginekologiju i
akušerstvo tokom 2011. i 2012. godine. Rezultati. Kod
trudnica sa dijabetesom tipa 1 poroĀaj se statistiÿki znaÿajno
ÿešýe završavao carskim rezom u odnosu na trudnice bez
dijabetesa i trudnice sa dijabetesom tipa 2 i gestacijskim di-
jabetesom (p < 0,0001), kao i ranijoj nedelji gestacije u od-
nosu na trudnice  bez dijabetesa i trudnice sa tipom 2 i
gestacijskim dijabetesom (p < 0,0017, p = 0,02). Kod trud-
nica sa dijabetesom statistiÿki znaÿajno veýa bila je uÿesta-
lost hipoglikemije (p < 0,0001), patološkog ikterusa (p =
0,0021) i druge patologije ploda na roĀenju (p = 0,0031) u
odnosu na kontrolnu grupu zdravih trudnica uz lošije vred-
nosti Apgar scora u 1. minuti kod novoroĀenÿadi (p =
0,0142) i 5. minutu (p = 0,0003). Trudnice sa dijabetesom
tipa 2 i gestacijskim dijabetesom bile su statistiÿki znaÿajno
starije nego trudnice sa dijabetesom tipa 1 (p = 0,001). Veýa
uÿestalost makrozomije ploda kod trudnica sa gestacijskim i
dijabetesom tipa 2 u odnosu na tip 1 bila je na granici statis-
tiÿke znaÿajanosti (p = 0,07), dok su hipoglikemije bile sta-
tistiÿki znaÿajno ÿešýe u grupi trudnica sa dijabetesom tipa 1
(p < 0,0001). Vrednosti glikozilovanog hemoglobina
(HbA1c) bile su statistiÿki znaÿajno više kod trudnica sa di-
jabetesom poroĀenih tokom i pre 36. gestacijske nedelje  (p
= 0,0087), bez razlike u vrednostima HbA1c u odnosu na
makrozomiju ploda (p = 0,45) i kongenitalne malformacije
(p = 0,32). Zakljuÿak. Rezultati našeg ispitivanja pokazuju
višu uÿestalost perinatalnog fetalnog morbiditeta (hipo-
glikemije, ikterusa, respiratornog distres sindroma) kod
bolesnica sa tipom 1, tipom 2 i gestacijskim dijabetesom u
odnosu na kontrolnu grupu zdravih trudnica. TakoĀe, kod
trudnica sa dijabetesom tipa 1 poroĀaj se ÿešýe završavao
carskim rezom nego kod trudnica sa dijabetesom tipa 2 i
gestacijskim dijabetesom i zdravih trudnica. Iako se trud-
noýa kod trudnica sa dijabetesom tipa 1, tipa 2 i gestacijskim
dijabetesom završavala jednu do dve nedelje ranije nego kod
zdravih trudnica, nije bilo statistiÿki znaÿajne razlike u
uÿestalosti prevremenog poroĀaja ( 36. nedelje gestacije)
izmeĀu žena sa dijabetesom i zdravih trudnica. Prevremeni
poroĀaj bio je povezan sa lošijom glikemijskom kontrolom
iskazanom kroz više vrednosti glikoziliranog hemoglobina u
treýem trimestru. Rizik od neželjenih ishoda trudnoýe može
se redukovati adekvatnim prekoncepcijskim savetovanjem
bolesnica sa dijabetesom i pravovremenom dijagnozom di-
jabetesa u trudnoýi, uz imperativ postizanja gotovo normo-
glikemijskog stanja kako u periodu organogeneze, tako i to-
kom cele trudnoýe uz timski rad endokrinologa, ginekologa
i pedijatra.
Kljuÿne reÿi:
diabetes melitus; trudnoýa; trudnoýa, razvoj fetusa;
poroĀaj, prevremeni; morbiditet.
Introduction
Impaired glucose metabolism is among the most com-
mon pregnancy-associated metabolic disorders occurring in
3–10% of all pregnancies. Gestational diabetes accounts for
88% of cases of diabetes in pregnancy, pre-existing diabetes
type 2 accounts for 8%, and pre-existing type 1 for 4% 
1, 2.
Epidemiological studies show that the prevalence of diabetes
among reproductive-age women is increasing, probably due
to insufficient physical activity, inadequate diet, and a great
number of obese children and adolescents. That is why today
more attention is paid to the problem of pre-existing diabetes
type 2 in pregnancy and increasing incidence of gestational
diabetes 
3–5. Up to the discovery and use of insulin, only a
small number of pregnancies in diabetic women have been
reported. In the 80’s of the last century, risks of diabetes-
related complications during pregnancy were 50% higher
than in healthy pregnant women 
2. Although current insulin
therapy has improved the quality of glycemic control,
women with diabetes, especially those with type 1 diabetes
compared with women without diabetes, have worse preg-
nancy outcomes, as well as increased incidence of spontane-
ous abortions, pre-eclampsia, fetal macrosomia, preterm de-
livery, congenital anomalies and perinatal mortality 
5–8. Nu-
merous studies have shown that the incidence of adverse
pregnancy outcomes in women with type 2 diabetes is the
same as in women with type 1 diabetes, and worse than in
the population of healthy women 
3, 6, 7. Gestational diabetes is
defined as any degree of glucose intolerance with onset or
first recognition during pregnancy 
1, 2. The most important
risk factors for gestational diabetes include sedentary life-
style, unbalanced diet, poor physical activity, obesity, family
history of diabetes, and previous history of macrosomia. That
is why oral glucose tolerance test (OGTT) is recommended
to all pregnant women at risk for gestational diabetes.
Women are recommended to take a 2-hour OGTT with 75
grams of glucose between their 24th and 28th week of preg-
nancy, and those at high risk of establishing pregnancy as
well 
1, 4, 5. For diagnosis of gestational diabetes it is sufficient
to detect only one pathological value during 2 hour OGTT:
blood glucose  5.1 mmol/L at the start,  10.0 mmol/L after
first hour and  8.5 mmol/L after second hour of the test. In
diagnosis of pre-existing diabetes mellitus (type 1 and type
2) a few criteria are in the use: fasting blood glucose  7.0
mmol/L, postprandial blood glucose  11.1 mmol/L and/or
glycosylated hemoglobin (HbA1c)  6.5% 
1.
Many studies showed that adverse pregnancy outcomes
(congenital anomalies, spontaneous abortions and perinatal
mortality) were associated with poor glycemic control in the
early pregnancy 
6–8. The critical period is before 7 weeks of
gestation, that is during organogenesis. Preconception coun-
seling is of utmost importance aiming at good glycemic con-
trol during preconception and in the early weeks of gestation
(WG). According to the recommendations of the American
Diabetes Association, target glycemic control parameters are
clearly defined: fasting blood glucose < 5.3 mmol/L; 1 hVolumen 71, Broj 10 VOJNOSANITETSKI PREGLED Strana 909
Mitroviý M, et al. Vojnosanit Pregl 2014; 71(10): 907–914.
postprandial blood glucose < 7.8 mmol/L; 2h postprandial
blood glucose  < 6.7 mmol/L; HbA1c between 6.0% and
6.5% 
1.
There are clearly defined protocols and recommenda-
tions for monitoring diabetic pregnant women, depending on
the gestational age of pregnancy 
2, 5, 9. In the first trimester it
is recommended to attend control of an endocrinologist and
gynecologist once a month, to control HbA1c value every 4–
6 weeks, regular day-night blood glucose profile control
(glycemia daily inspection before each meal and at bedtime,
and also 2–3 times weekly 1–2 hours after each meal and
during the night), control of TSH, free T4 (before conception
and in the first trimester), control of urea, creatinine, 24 hour
proteinuria, complete blood count, urine, arterial tension and
cardiovascular status, monitoring body weight, and oph-
thamological examination.
In the second, and especially in the third trimester
controls become more frequent. Monitoring of glycemic
profile becomes daily and control of glycosuria, acetonuria
and HbA1c, as well as control of endocrinologist is rec-
ommended firstly every four weeks and later every two
weeks. Control of urea, creatinine, 24 hour proteinuria,
hepatogram (in suspected preeclampsia), urine, arterial ten-
sion, cardiovascular status and weight control is recom-
mended at each visit to the doctor. Ophthalmological ex-
amination is obliged in the week of gestation 28, and in the
presence of retinopathy in the period between the week of
gestation 16 and 20.
Pregnant women with diabetes should be offered ultra-
sound monitoring of fetal growth and amniotic fluid volume
every 4 weeks from 28 to 36 weeks. Women with diabetes
and macrovascular disease and/or nephropathy will require
an individualised approach to monitoring fetal growth and
wellbeing 
2, 5.
Diabetes mellitus is not an indication for cesarean sec-
tion unless there are some other obstetric indications (fetal
macrosomia, feto-pelvic disproportion, etc.) or maternal
complications (advanced chronic complications of diabetes,
eclampsia). But, evidence shows that women with diabetes
are more likely to undergo induction of labour and/or caesar-
ean section at 38–39 week of gestation than women without
diabetes to prevent stillbirth and shoulder dystocia, which are
associated with fetal macrosomia 
5.
Elective birth should be offered after completed the
week of gestation 38 in the cases of a good metabolic control
of diabetes, absence of abnormalities of the fetus, respiratory
distress syndrome and other obstetric and maternal compli-
cations. Preterm delivery is indicated in cases of poor meta-
bolic control of diabetes, fetal growth acceleration or intrau-
terine fetal growth retardation, fetal respiratory distress syn-
drome, polyhydramnios or other obstetric and/or maternal
complications 
3, 5.
The aim of this study was to analyze  the components of
maternal and perinatal morbidity in pregnant women with
diabetes in relation to the group of healthy pregnant women
and separately among the groups with pre-existing type 1
diabetes and  gestational and type 2 diabetes, as well as to
assess a correlation of  components of metarnal and perinatal
outcomes in regard to  glycemic control, duration of diabetes
and chronic complications.
Methods
This retrospective study included 156 diabetic women
in the week of gestation 28–32 treated at the Clinic of Endo-
crinology, Diabetes and Metabolic Diseases and Gynecology
and Obstetrics Clinic of the Clinical Center of Vojvodina,
Novi Sad, from 2006 to 2010. There were 94 patients with
gestational diabetes, 48 with type 1 diabetes, and 14 with
type 2 diabetes. Considering a small number of women with
type 2 diabetes diagnosed with diabetes mellitus before
pregnancy and treated only with diet and/or metformin ther-
apy, bearing in mind similar etiopathogenetic mechanism as
gestational diabetes, we included them in the same group for
statistical analysis. The control group included 106 healthy
women also in the week of gestation 28–32 giving birth at
the Gynecology and Obstetrics Clinic of the Clinical Center
of Vojvodina during 2011 and 2012. The control group was
randomly selected among healthy pregnant women hospital-
ized in 2011 and 2012 considering the fact that socioeco-
nomic living conditions, health care system and management
of pregnancy were not changed in relation to the period
2006–2010. The following parameters were studied: mater-
nal age, arterial hypertension (blood pressure over 140/90
mmHg or use of antihypertensive therapy), and pre-
eclampsia during pregnancy (the diagnosis of pre-eclampsia
was made after the week 20 of gestation in cases with a arte-
rial hypertensia and proteinuria > 300 mg/24 h), type of de-
livery (vaginal or cesarean), gestational age at delivery, and
the number of spontaneous abortions in previous pregnan-
cies. Neonatal characteristics included Apgar scores, birth
weight, birth length, hypoglycemia, jaundice or any other
perinatal morbidity and perinatal mortality. These groups
were also examined for differences in HbA1c levels, whereas
in patients with diabetes type 1 types of insulin therapy and
incidence of microvascular complications of diabetes were
investigated as well. Statistical data processing was carried
out by t-test and test of proportion.
Results
Table 1 shows perinatal and maternal outcomes among
the pregnant women with type 1 diabetes and the healthy
control. The incidence of delivery by cesarean section was
statistically significantly higher compared to the non-diabetic
women (p < 0.0001), and the women with type 1 diabetes
were more likely to deliver earlier than women without dia-
betes (37.9 weeks of gestation vs 39.09 weeks of gestation,
respectively,  p < 0.0017). In addition, perinatal morbidity
was statistically significantly higher in the diabetic women
compared to the healthy controls: hypoglycemia (p < 0.001),
pathological jaundice (p = 0.0021), and other causes of neo-
natal morbidity (p = 0.0031). Accordingly, Apgar scores af-
ter 1 minute (p = 0.0142) and after 5 minutes (p = 0.0003)
were statistically significantly lower in the diabetic than in
non-diabetic women. There were no differences in birthStrana 910 VOJNOSANITETSKI PREGLED Volumen 71, Broj 10
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weight and birth length of newborns between the two exam-
ined groups. However, in regard to birth weight, one must
bear in mind that pregnancies in the women with diabetes
completed on the average 1–2 weeks earlier than in the
women without diabetes, so it may be assumed that the new-
borns of the women with diabetes would have had a statisti-
cally significantly higher birth weight if they had been born
in the same week of gestation as the newborns of the healthy
controls. There were no statistically significant differences
between these two groups of women in relation to the inci-
dence of congenital abnormalities, spontaneous abortions in
previous pregnancies and stillbirths.
Table 2 shows characteristics of the patients with type 1
diabetes related to perinatal fetal morbidity. The women
whose infants exhibited perinatal morbidity (hypoglycemia,
jaundice, diabetic fetopathy, respiratory distress syndrome)
had longer duration of diabetes, higher incidence of chronic
complications, lower glucose control, but these differences
were not statistically significant. In addition, there were no
statistically significant differences regarding the incidence of
cesarean section and lower gestational age at birth, birth
weight and birth length. A statistically significant difference
was only found in Apgar score value in the 1 minute (p =
0,036).
Table 3 shows perinatal and maternal outcomes ob-
served among the pregnant women with type 1 diabetes
compared with women with type 2 diabetes and gestational
diabetes.
The patients with type 2 diabetes and gestational diabetes
were statistically significantly older than the patients with type
1 diabetes (p = 0.001). The glycemic control was better in the
patients with type 2 diabetes and gestational diabetes than in
the patients with type 1 diabetes (p < 0.0001). The incidence
of hypertension and pre-eclampsia was higher in the patients
with type 2 diabetes and gestational diabetes, but the differ-
ence was not statistically significant. The incidence of cesar-
ean section (p = 0.0001) and completion of pregnancy 1–2
weeks before full-term (p = 0.0093) were statistically signifi-
Table 2
Characteristics of the patients with type 1 diabetes related to perinatal fetal morbidity
Parameters Without fetal morbidity With fetal morbidity p
Age (years), ʉ ± SD 29.93 ± 4.73 28.36 ± 5.29 0.3426
Duration of diabetes (years), ʉ ± SD 8.00 ± 5.71 11.91 ± 6.86 0.0608
Insulin analogue therapy (%) 33.33 45.45 0.9470
Microvascular diabetic
complications (%)
13.33 25.81 0.5614
HbA1c (%), ʉ ± SD 6.48 ± 0.90 7.10 ± 1.14 0.1139
Arterial hypertension (%) 6.67 9.37 0.8014
Pre-eclampsia (%) 6.67 0.00 0.6945
Spontaneous abortions in previous
pregnancies (%)
26.67 24.24 0.8577
Gestational age at birth (weeks),
ʉ ± SD
38.09 ± 0.81 37.81 ± 1.81 0.5712
Cesarean section (%) 85.71 75.00 0.6731
Apgar score I, ʉ ± SD 8.47 ± 0.99 7.61 ± 1.38 0.0367
Apgar score II, ʉ ± SD 9.00 ± 0.53 8.68 ± 1.11 0.2970
Birth weight (g), ʉ ± SD 3362.67 ± 386.97 3510.94 ± 646.85 0.4172
Birth length (cm), ʉ ± SD 50.07 ± 1.83 50.44 ± 2.66 0.6292
Table 1
Perinatal and maternal outcomes observed among the pregnant women with type 1 diabetes and the healthy controls
Parameters Patients with type 1 diabetes Healthy controls p
Age (years), ʉ ± SD 28.83 ± 5.13 30.57 ± 5.15 0.0537
Arterial hypertension (%) 8.51 10.38 0.9450
Pre-eclampsia (%) 2.13 6.60 0.4443
Spontaneous abortions in previous
pregnancies (%)
25.40 14.15 0.1422
Gestational age at delivery (weeks), ʉ ± SD 37.90 ± 1.55 39.09 ± 2.36 0.0017
Delivery  36 WG (%) 14.58 9.43 0.5047
Cesarean section (%) 78.26 35.85 < 0.0001
Apgar score I, ʉ ± SD 7.91 ± 1.33 8.57 ± 1.61 0.0142
Apgar score II, ʉ ± SD 8.78 ± 0.97 9.39 ± 0.93 0.0003
Birth weight (g), ʉ ± SD 3463.62 ± 576.57 3396.60 ± 697.28 0.5617
Birth length (cm), ʉ ± SD 50.32 ± 2.41 49.70 ± 3.24 0.2380
Fetal hypoglycemia (%) 52.17 1.88 < 0.0001
Fetal jaundice (%) 50.00 23.58 0.0021
Other fetal morbidity at birth (%) 68.75 41.51 0.0031
Congenital malformations (%) 6.83 13.21 0.3755
Fetal macrosomia (%) 10.42 16.98 0.4157
Stillbirth (%) 4.20 0.00 0.1743Volumen 71, Broj 10 VOJNOSANITETSKI PREGLED Strana 911
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cantly higher in the patients with type 1 diabetes than in
those with type 2 and gestational diabetes. Perinatal morbid-
ity was statistically significantly higher in the patients with
type 1 diabetes, especially hypoglycemia (p < 0.0001). There
were no statistically significant differences in relation to
birth weight, birth length, and Apgar scores of newborns
between the patients with type 1 diabetes and those with type
2 diabetes and gestational diabetes. The incidence of fetal
macrosomia was higher in the patients with gestational and
type 2 diabetes (24.11%) than in those with type 1 diabetes
(10.4%), that is considered as borderline statistical signifi-
cance. The incidence of preterm delivery was higher in the
patients with type 1 diabetes (14.58%) in relation to the pa-
tients with gestational and type 2 diabetes  (5.35%), but the
difference was not statistically significant. In addition, there
was no statistically significant difference in the incidence of
congenital abnormalities and spontaneous abortions in previ-
ous pregnancies between the patients with diabetes type 1
and those with diabetes type 2 and gestational diabetes.
Table 4 shows perinatal and maternal outcomes ob-
served among the pregnant women with type 2 diabetes and
gestational diabetes in relation to the healthy controls.
There were no statistically significant age related dif-
ferences between the patients with diabetes and healthy con-
trols. There were also no statistically significant differences
in the incidence of hypertension, pre-eclampsia and cesarean
section between these two groups. In the patients with type 2
diabetes and gestational diabetes, pregnancies ended at the
Table 3
Perinatal and maternal outcomes observed among the pregnant women with type 1 diabetes compared with the women
with type 2 and gestational diabetes
Parameters Patients with
type 1 diabetes
Patients with type 2 diabetes and
gestational  diabetes
p
Age (years), ʉ ± SD 28.83 ± 5.13 31.89 ± 5.32 0.0010
HbA1c (%), ʉ ± SD 6.85 ± 1.14 5.85 ± 0.79 < 0.0001
Arterial hypertension (%) 8.51 15.32 0.3701
Pre-eclampsia (%) 2.13 4.54 0.7895
Spontaneous abortions in
previous pregnancies (%)
25.40 17.86 0.3816
Gestational age at delivery
(weeks), ʉ ± SD
37.90 ± 1.55 38.50 ± 1.19 0.0093
Delivery  36 WG (%) 14.58 5.35 0.1004
Cesarean section (%) 78.26 41.28 0.0001
Apgar score I, ʉ ± SD 7.91 ± 1.33 8.10 ± 1.16 0.3760
Apgar score II, ʉ ± SD 8.78 ± 0.97 8.93 ± 0.91 0.3616
Birth weight (g), ʉ ± SD 3463.62 ± 576.57 3570.72 ± 579.48 0.2892
Birth length (cm), ʉ ± SD 50.32 ± 2.41 50.58 ± 2.18 0.5077
Fetal hypoglycemia (%) 52.17 16.51 < 0.0001
Fetal jaundice (%) 50.00 49.54 0.9017
Other fetal morbidity at birth (%) 68.75 45.54 0.0117
Congenital malformations  (%) 6.83 7.14 0.7896
Fetal macrosomia (%) 10.42 24.11 0.0770
Stillbirth (%) 4.20 0.00 0.1721
Table 4
Perinatal and maternal outcomes observed among the pregnant women with type 2 diabetes and gestational diabetes in
relation to the healthy controls
Parameters Patients with type 2 and
gestational diabetes
Healthy controls p
Age (years), ʉ ± SD 31.89 ± 5.32 30.57 ± 5.15 0.0643
Arterial hypertension (%) 15.32 10.38 0.3762
Pre-eclampsia (%) 4.54 6.60 0.7126
Cesarean section (%) 41.28 35.85 0.4941
Spontaneous abortions in previous
pregnancies (%)
17.86 14.15 0.5747
Delivery  36 WG (%) 5.35 9.43 0.3708
Gestational age at delivery (weeks), ʉ ± SD 38.50 ± 1.19 39.09 ± 2.36 0.0197
Apgar score I, ʉ ± SD 8.10 ± 1.16 8.57 ± 1.61 0.0138
Apgar score II, ʉ ± SD 8.93 ± 0.91 9.39 ± 0.93 0.0003
Birth weight (g), ʉ ± SD 3570.72 ± 579.48 3396.60 ± 697.28 0.0457
Birth length (cm), ʉ ± SD 50.58 ± 2.18 49.70 ± 3.24 0.0190
Fetal hypoglycemia (%) 16.51 1.88 0.0005
Fetal jaundice (%) 49.54 23.58 0.0001
Other fetal morbidity at birth (%) 45.54 41.51 0.6433
Congenital malformations (%) 7.14 13.21 0.2069
Fetal macrosomia (%) 24.11 16.98 0.2574
Stillbirth (%) 0.00 0.00 –Strana 912 VOJNOSANITETSKI PREGLED Volumen 71, Broj 10
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week of geastation 38.5, that was statistically significantly
earlier compared to the control group – the week of gestation
39.09 (p = 0.02). However, Table 4 also shows that the pa-
tients with diabetes exhibited a statistically significantly
higher incidence of hypoglycemia (p = 0.0005), pathological
jaundice (p = 0.0001), birth weight (p = 0.0457), and birth
length (p = 0.019), first minute Apgar score (p = 0.0138),
and 5 minute Apgar score (p = 0.0003), compared to healthy
controls. Nevertheless, we should keep in mind that pregnant
women with diabetes completed their pregnancies on the av-
erage one week earlier than the healthy controls, which
probably affected lower incidence of fetal macrosomia.
Table 5 shows HbA1c values in relation to birth weight,
week of gestation at delivery and congenital anomalies
among the pregnent women with diabetes.
The women giving birth before the week of gestation 36
presented with a statistically significantly higher levels of
HbA1c in relation to those completing their pregnancies after
the week of gestation 36 (p = 0.0087), but there were no sta-
tistically significant differences in the levels of HbA1c in
relation to macrosomia and congenital anomalies.
Discussion
In recent decades, due to current insulin therapy,
monitoring of pregnant women with diabetes, counseling,
preconception care and strict glucose control, the incidence
of perinatal mortality and congenital abnormalities showed a
significant reduction in diabetic patients 
9–12. However, de-
spite improvements in glycemic control, the incidence of fe-
tal macrosomia is still 20–40%. Fetal macrosomia is usually
defined as birth weight over 95% 
13, 14. Macrosomia is recog-
nized as a cause of fetal morbidity and mortality and despite
relatively good glycemic control, its incidence is statistically
higher in mothers with  diabetes in relation to non-diabetic
mothers. Macrosomia also increases maternal morbidity, fre-
quently requiring instrumental delivery or cesarean section.
It seems that accelerated fetal growth is determined by
HbA1c levels in the first half of pregnancy and it continues
despite improved glycemic control in the second half of
pregnancy.
Maternal hyperglycemia leads to fetal hyperglycemia
and consequently to fetal pancreatic beta-cell hyperplasia.
Poon et al. 
15 investigated 33,602 women and found that in-
fant birth weight was associated not only with pre-existing
and/or gestational diabetes, but also correlated with maternal
weight and height, and that it was higher in multipara in re-
gard to nulipara. In our study, there were no statistically sig-
nificant differences in infant birth weights of mothers with
type 1 diabetes and those of healthy controls. This is partly a
consequence of the fact that pregnancies in women with type
1 diabetes are completed on the average one or two weeks
earlier compared to healthy controls. Our results show that
the incidence of neonatal macrosomia was highest in patients
with type 2 diabetes and gestational diabetes (24.11%) com-
pared to patients with type 1 diabetes (10.5%) and healthy
controls (16.98%), but these differences were not statistically
significant. These results can be explained by the fact that on
the average glycemic control in our diabetic patients (HbA1c
of 6.5%) was satisfactory, and it is well-known that fetal
macrosomia is mostly associated with high HbA1c levels in
the second and third trimesters of pregnancy. This is cer-
tainly contributed by the fact that delivery in patients with
diabetes type 1 is usually planned between the week of ges-
tation 36 and 38 and particularly in those with obstetrically
verified accelerated fetal growth. A higher incidence of fetal
macrosomia in patients with type 2 diabetes and gestational
diabetes than in patients with type 1 diabetes may be because
fetal macrosomia is affected not only by diabetes, but also by
maternal obesity, which is more often associated with type 2
diabetes and gestational diabetes.
During labor and birth process, infants of mothers with
diabetes are at increased risk for neonatal hypoglycemia, due
to interrupted glucose supply and hyperinsulinism 
2, 16. Peri-
natal stress is also associated with neonatal hypoglycemia, in
part because of catecholamine and glycocorticoid-stimulated
mobilization and depletion of glycogen stores. Reactive hypo-
glycemia occurs within 2 hours after childbirth and persists up
to 72 hours, but may last up to one week. Up to 50% of infants
of mothers with type 1 diabetes experience hypoglycemia after
birth. The results of our study are in accordance with these re-
sults showing that the incidence of neonatal hypoglycemia was
52% in mothers with type 1 diabetes, and 16.5% in mothers
with type 2 diabetes or gestational diabetes. Both groups of
diabetic mothers presented with a statistically significantly
higher incidence of neonatal hypoglycemia compared to
healthy controls without recorded hypoglycemia. Hrabovski et
al. 
16 also established a higher incidence of hypoglycemia, hy-
pocalcemia and hypomagnesemia in infants of diabetic moth-
ers compared to healthy controls.
The incidence of hypoglycemia is higher in macrosomic
infants, but also in infants with low birth weight in relation to
Table 5
HbA1c as a parameter of glycemic control, among the pregnant women with diabetes (type 1, type 2 and gestational) in
relation to birth weight, week of gestation (WG) at delivery and congenital anomalies
Parameters HbA1c (%),  ʉ ± SD p
Birth weight > 4000 g 6.04 ± 0.88
Birth weight < 4000 g 6.26 ± 1.07 0.4515
Delivery  36 WG 6.78 ± 1.31
Delivery > 36 WG 6.18 ± 1.00 0.0087
With congenital anomalies 6.55 ± 1.47
Without congenital anomalies 6.19 ± 1.01 0.3255
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infants with normal birth weight. Neonatal hypoglycemia in
infants small-for-date is the consequence of intrauterine
growth retardation, often found in mothers with long-term
diabetes and chronic vascular complications 
2, 17, 18. Newborn
infants of diabetic mothers are also at increased risk of hy-
perbilirubinemia, which is explained by increase in the red
blood cell count and mass, ineffective erythropoiesis and
relative immaturity of hepatic conjugation and bilirubin ex-
cretion 
2, 17, 18. Both groups of diabetic women (type 1 and
type 2 or gestational diabetes) presented with 50% of patho-
logical neonatal jaundice, which is statistically significant in
regard to healthy controls. These results are in agreement
with the results of numerous previous studies, which con-
firmed the occurrence of pathological jaundice in neonates of
diabetic women 
17, 18.
The perinatal mortality is about five times higher in
women with diabetes than in those without diabetes. Apart
from carbohydrate metabolism disorders, diabetes is also as-
sociated with metabolic disorders involving fats, proteins,
and amino acids, all of which inevitably affects fetal gene
expression and increases teratogenicity. Risks of fetal death
are certainly associated with maternal obesity, hypertension,
advanced age and long-term diabetic complications 
19, 20. In
our study, stillbirths were recorded only in patients with type
1 diabetes (4.2%), whereas the percentage of stillbirths in
previous pregnancies was 1.7%, that was not statistically
significant in relation to healthy controls and patients with
type 2 diabetes and gestational diabetes, where the percent-
age of stillbirths in previous pregnancies was 0.9% and there
were no recorded stillbirths in actual pregnancies. Spontane-
ous abortion is the best indicator of glycemic control in the
preconception period and the early weeks of pregnancy. In-
vestigations have documented that HbA1c levels above 11%
increase risks of early spontaneous abortions by over
40% 
21, 22 Although the incidence of spontaneous abortions
was higher in patients with type 1 diabetes compared to pa-
tients with gestational, and type 2 diabetes, and healthy con-
trols, the difference was not statistically significant. The in-
cidence of congenital malformations is 3–5 times higher in
women with pre-existing diabetes than in healthy controls,
and there is no difference between patients with type 1 and
type 2 diabetes. Congenital anomalies often cause stillbirth,
especially cardiovascular anomalies and neural tube defects.
However, according to the same data, maternal diabetes
alone is not a predictive factor of specific anomalies 
2, 
21.
Although literature data mostly suggest that the incidence of
congenital anomalies is higher in women with diabetes, our
study showed no statistically significant differences in rela-
tion to the healthy controls 
21, 22. HbA1c levels were higher in
women with fetal congenital abnormalities in regard to those
without them, but the difference was not statistically signifi-
cant. Major congenital malformations are most commonly
associated with hypeglycemia in the preconception period
and during organogenesis, but some authors reported about
certain nervous system malformations associated with hypo-
glycemia in the first trimester. Preterm births are closely as-
sociated with perinatal mortality and morbidity. One third of
preterm births are among mothers with pregestational diabe-
tes. It is believed that the percentage of preterm deliveries
(spontaneous and induced) in women with diabetes type 1 is
about 45%. The most important predictive factors for pre-
term delivery include poor glycemic control and vascular
complications (pre-eclampsia and nephropathy) 
23. In our
study, there was statistically significantly poorer glycemic
control in the women which gave birth before the week of
gestation 36, and that matches with literature data 
23. Type 1
diabetic patients had more frequent preterm delivery and the
most of the cases occurred between the week of gestation
34–36, in regard to patients with type 2 and gestational dia-
betes and healthy subjects, but without a statistically  signifi-
cant difference. The Confidential Enquiry into Maternal and
Child Health (CEMACH) has also reported that the preterm
delivery rate is 5 times higher in patients with type 1 and
type 2 diabetes compared to general population 
5. About 2/3
of preterm deliveries are medically induced, most often due
to fetal complications. The occurrence of hypertension in
patients with diabetes type 1 is commonly the consequence
of the onset and/or progression of diabetic nephropathy,
whereas patients with diabetes type 2 mostly present with
essential hypertension, as part of the cardiometabolic syn-
drome. Both groups of patients are at higher risk for devel-
oping pre-eclampsia, especially patients with pre-existing
diabetic nephropathy 
23, 24. The above-mentioned maternal
vascular complications have been consistently associated
with pre-term delivery, perinatal fetal morbidity and mor-
tality 
25. In patients with type 1, type 2 and gestational dia-
betes, the incidence of hypertension and pre-eclampsia was
not statistically significantly different compared to healthy
controls. The incidence of hypertension and pre-eclampsia
was slightly higher in patients with gestational and type 2
diabetes in relation to patients with diabetes type 1, but the
difference was not statistically significant. These results
can be explained by the fact that the majority of patients
with type 1 diabetes, compared to those with type 2 diabe-
tes or gestational diabetes, get pregnant at a younger age,
with a shorter duration of diabetes, without diabetic ne-
phropathy or in its incipient phase. Patients with type 1
diabetes and perinatal morbidity presented with longer du-
ration of diabetes, higher incidence of microvascular com-
plications (macrovascular complications were not diag-
nosed), hypertension and higher HbA1c levels. The above-
mentioned differences were not statistically significant,
maybe due to a small number of patients with type 1 dia-
betes included in the study.
Conclusion
The results of our study show a higher incidence of
perinatal fetal morbidity (hypoglycemia, jaundice, respira-
tory distress syndrome) in the patients with type 1, type 2
and gestation diabetes than in the healthy control. Also, we
found a higher incidence of cesarean section in the patients
with type 1 diabetes than in those with type 2 diabetes, ges-
tation diabetes and healthy control. Although delivery in the
patients with type 1, type 2 and gestational diabetes was
completed approximately one to two weeks earlier comparedStrana 914 VOJNOSANITETSKI PREGLED Volumen 71, Broj 10
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to the healthy control group there was no statistically signifi-
cant difference in the incidence of preterm delivery (before
the week of gestation 36) between the women with diabetes
and the healthy control group. Preterm delivery associated
with poorer glycaemic control reflected through higher val-
ues HbA1c in third trimester. Bearing in mind that the men-
tioned complications are usually associated with hypergly-
cemia, it is necessary to provide adequate preconception
counseling of diabetic patients, timely diagnosis of diabetes,
and good glycemic control both during organogenesis and
throughout pregnancy, in order to reduce adverse pregnancy
outcomes to minimum.  
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